Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation - Wikidata - wikimedia - TriplyDB

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

http://www.wikidata.org/entity/Q27684731

about

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?The PTEN tumor suppressor gene and its role in lymphoma pathogenesis Using hydrogen deuterium exchange mass spectrometry to engineer optimized constructs for crystallization of protein complexes: Case study of PI4KIIIβ with Rab11 Therapeutic targeting of cancers with loss of PTEN function.Targeting Plasmodium PI(4)K to eliminate malaria Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR Somatic Activating PIK3CA Mutations Cause Venous Malformation PI3Kα inhibition reduces obesity in mice PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.Structural basis of nSH2 regulation and lipid binding in PI3Kα.Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.Selective and potent small-molecule inhibitors of PI3Ks.Phosphoinositide 3-kinase alpha-dependent regulation of branching morphogenesis in murine embryonic lung: evidence for a role in determining morphogenic properties of FGF7 Detection and manipulation of phosphoinositides.Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT).Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.Discovery and functional characterization of a neomorphic PTEN mutation.PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents.Gene of the month: PIK3CA.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Emerging use of everolimus in the treatment of neuroendocrine tumors.The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.

P2860

Q24336818-34533B64-6B13-4102-8049-7267B6ACF3B0 Q26740374-2DA7281C-FE24-401D-9075-AF1D43642CD1 Q26744721-B3761711-7F0F-476F-A136-D6B16BDC8862 Q26775940-3BADF138-905C-451B-83FC-BDC67FCE1E99 Q26776527-EC2CD4F4-09A3-441A-9F92-7895310CA188 Q27644406-C0B47EBC-89BF-41DA-8CE6-0DBAF0CA9617 Q27852764-2E2A2180-708F-4458-865B-2EEBC56DF332 Q27974482-D1D5201C-30E4-4319-B517-4D92532409F3 Q28086993-1D2A7691-A1C8-4E34-ACA0-072745B8084A Q28270654-D9FD7880-2E4D-4245-AB52-F7EE7C16E50B Q28818545-7E5E6076-F1F5-4A74-A12E-8C99D19B0740 Q33618630-88C9E5A7-F986-42D1-BEDA-82209D0F6BD2 Q33674643-AEB9C9ED-D40D-4D91-BBD1-DF50B49D9BF5 Q33734538-1243A19C-6B50-45AC-A023-8FCEEC8A568F Q33776641-F8612996-37FF-4B99-8853-24BB35569E09 Q33804713-F5C5AE59-DD40-4FD4-81B6-0FC3B0953FF2 Q34096861-0A5912C6-D41E-4E1E-BDAA-68E766A6D95A Q34221876-972BC423-A8F3-4D9C-AF82-5E83551EA25D Q34571048-3881B8A9-E8E0-4209-9615-6E06A4323A02 Q35060792-E28D57EF-DD15-4991-8E07-5E3C37FC1D79 Q35174681-E8C87DF8-BA09-4BED-843F-079EECB1EBF7 Q35190512-4650E540-0AA6-419B-ACB1-616184DD75CE Q35474166-885F2A69-3E5F-44DF-B3B7-548B6BDF3F0C Q35525004-56F4A094-4570-40BA-8723-38712A04431C Q35640508-1E197D31-A450-4425-932F-C3CFEBC53BCE Q36070390-822EB563-3A3C-4986-AC17-7F81E516CEC1 Q36262959-6CBB301F-5AE5-4ED8-9332-67C9A428ADCF Q36300265-B44CD420-339F-4959-9EDD-0CBE84AA10B7 Q36378189-3D40DD63-D58B-4290-AEB5-1345F06FACBE Q36997524-4C104D3E-4DEF-4F59-A5BC-FE8FC8AF4EE9 Q37517706-C265C40B-64B6-4B9C-8F36-F91EB4F1CF6B Q37587308-542B0374-6FFA-460F-9636-6D88F363A70C Q37679937-FBC034E9-10E9-4AFC-86AC-2A00818A0CB6 Q38180768-8309768F-9A33-4ED4-A2D8-4D0704102776 Q38285703-A4C160D5-3F46-41F9-95EA-DD0085D789AF Q38358055-7624DAFA-49D6-46CF-BE7A-129A69496F8F Q38554422-5AE87D03-8826-4E78-B7FA-90B797DF41BC Q38661603-3CA11609-06A8-4410-8C00-7192A6375435 Q38695102-6F8B0F2B-3C8E-4777-8280-069E058C8FD1 Q38699761-5046171B-7E84-4A1A-894C-008D77FF7349

P2860

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

http://www.wikidata.org/entity/Q27684731

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@ast

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@en

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@nl

type

label

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@ast

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@en

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@nl

prefLabel

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@ast

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@en

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@nl

P1433

Q27684731-F439B8AD-931E-4FBA-B968-2A3D749D7E78

P1476

Q27684731-A6259264-B159-454B-A12C-0AB908A8E45B

P2093

Q27684731-56F9A0DA-CE5B-4D44-9719-28F2B8C1ECD2

Q27684731-5BC013E3-7FBE-4202-A523-7D3B36489A36

Q27684731-63DE09A0-AB52-4C71-8926-F4247F3C8D77

Q27684731-8CBA8965-A629-4891-8FF4-9D78385CCC83

Q27684731-9D81E2A9-2091-48CC-9449-E7EC898D1A6F

Q27684731-AAC1F9F1-474C-4247-9E86-3206B767D731

Q27684731-B32502CD-1468-4A49-8CD6-BAB8F54F28D1

Q27684731-C3C2CFB4-E8E3-4595-90DA-DA7EE0D3B6D2

Q27684731-DB79C239-8641-4ABE-8790-BF6D7BDAD7D6

Q27684731-E1FA157D-EB1F-4452-9C3A-008915C5D6D9

P304

Q27684731-4729F61C-F4AC-4C19-94A1-452129D636EB

P31

Q27684731-46DF7C6B-2E07-4BEA-A1DC-8B24FA3E76EA

P3181

Q27684731-49575DD5-017E-4868-BFA3-F5D3D392C791

P356

Q27684731-BC7B9A52-179E-4FAE-A475-71492F462550

P407

Q27684731-E19D2691-D201-42D3-B834-E7758A6D9179

P433

Q27684731-EC42D7E8-09FE-43B6-9EE7-7F43C9AEAF58

P478

Q27684731-DF378C56-11F8-4B11-B983-8756995B2DF0

P50

Q27684731-C9F343A0-980B-4EDE-B43C-C1B82217856B

P577

Q27684731-40F09297-2F2A-4D31-A4E6-3424403BDBF3

P5875

Q27684731-44241239-A295-433E-BB76-29FF9403C611

P698

Q27684731-420986DC-42EE-4708-AFD8-A141A9298068

P3181

P356

J.BMCL.2013.05.007

P1433

Bioorganic & Medicinal Chemistry Letters

P1476

Discovery of NVP-BYL719 a pote ...... lected for clinical evaluation

@en

P2093

Christine Fritsch

http://www.w3.org/2001/XMLSchema#string

Doriano Fabbro

http://www.w3.org/2001/XMLSchema#string

Francesca Blasco

http://www.w3.org/2001/XMLSchema#string

Giorgio Caravatti

http://www.w3.org/2001/XMLSchema#string

Ian Bruce

http://www.w3.org/2001/XMLSchema#string

Jacques Hamon

http://www.w3.org/2001/XMLSchema#string

Mark Knapp

http://www.w3.org/2001/XMLSchema#string

Pascal Furet

http://www.w3.org/2001/XMLSchema#string

Patricia Imbach-Weese

http://www.w3.org/2001/XMLSchema#string

Reiner Aichholz

http://www.w3.org/2001/XMLSchema#string

P304

3741-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1771836

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.BMCL.2013.05.007

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237002254

http://www.w3.org/2001/XMLSchema#string

P698

23726034

http://www.w3.org/2001/XMLSchema#string